Shree Karthik P

Emmbi Ind

< -5%

Purv Flexipack

G K P Printing

TCPL Packaging

Worth Periphera

-5% to -3%

Texel Ind

Promact Plastic

Uflex

Anuroop Packag

Shree Ajit Pulp

AGI Greenpac

Shri Rama Multi

BB Triplewall 

Huhtamaki India

Shree Tirupati 

-3% to 0%

Uma Converter

0% to 3%

BA Packaging

3% to 5%

Pyramid Techno

HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners, Asio Fund VCC-Sub Fund 4, Vikasa India EIF I Fund - Share Class P sell 1.49% stake in Reva Diamonds, Indian Infotech and Software sells 40 lakh shares in Akme Fintrade

* HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners
* Asio Fund VCC-Sub Fund 4, Vikasa India EIF I Fund - Share Class P sell 1.49% stake in Reva Diamonds
* Indian Infotech and Software sells 40 lakh shares in Akme Fintrade

shorts/business/hdfc-mutual-fund-sells-shares-worth-rs-358-crore-in-sundram-fasteners

* HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners
* Asio Fund VCC-Sub Fund 4, Vikasa India EIF I Fund - Share Class P sell 1.49% stake in Reva Diamonds
* Indian Infotech and Software sells 40 lakh shares in Akme Fintrade

HDFC Mutual Fund on March 4 has offloaded over 2 percent equity stake in Sundram Fasteners that makes precision components for the automotive, infrastructure, windmill and aviation sectors, for nearly Rs 358 crore via open market transactions.

Sundram Fasteners shares declined 1.3 percent to finish the session at Rs 835.9 amid high volumes on the NSE. The stock has been under pressure for sixth straight day.

HDFC Mutual Fund sold 20.5 lakh shares in <a href="https://www.moneycontrol.com/india/stockpricequote/fasteners/sundramfasteners/SF23">Sundram Fasteners</a> at Rs 831.97 per share, and 22.48 lakh shares at Rs 832.36 per share, which is equivalent to 2.04 percent of paid-up equity valued at Rs 357.66 crore.

As of December 2025, HDFC Mutual Fund through HDFC NIFTY500 Multicap 50:25:25 Index Fund held 7.62 percent equity stake in the TVS Group company.

The brisk action was also seen in <a href="https://www.moneycontrol.com/india/stockpricequote/diamondjewellery/pngsrevadiamondjewellery/PRD">PNGS Reva Diamond Jewellery</a>, which outperformed the falling market, rising 6.66 percent to Rs 411.7 on the NSE despite institutional investors offloading 1.49 percent stake on its listing day today.

The Asio Fund VCC-Sub Fund 4, and Vikasa India EIF I Fund - Share Class P each sold 2.36 lakh shares in Reva Diamonds (0.74 percent stake each) for Rs 8.87 crore. The selling price for these shares was Rs 375 per share.

Meanwhile, Subhash Phootarmal Rathod has acquired 46 lakh shares in <a href="https://www.moneycontrol.com/india/stockpricequote/finance-investment/akmefintradeindia/AFIL">Akme Fintrade (India)</a> at Rs 7.24 per share for Rs 3.33 crore, however, Indian Infotech and Software sold 40 lakh shares at Rs 7.25 per share, valued at Rs 2.9 crore. Both are already investors in the company, holding 3.6 percent, and 1.12 percent stake, respectively.

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners

HDFC Mutual Fund on March 4 has offloaded over 2 percent equity stake in Sundram Fasteners that makes precision components for the automotive, infrastructure, windmill and aviation sectors, for nearly Rs 358 crore via open market transactions.

Sundram Fasteners shares declined 1.3 percent to finish the session at Rs 835.9 amid high volumes on the NSE. The stock has been under pressure for sixth straight day.

HDFC Mutual Fund sold 20.5 lakh shares in Sundram Fasteners at Rs 831.97 per share, and 22.48 lakh shares at Rs 832.36 per share, which is equivalent to 2.04 percent of paid-up equity valued at Rs 357.66 crore.

As of December 2025, HDFC Mutual Fund through HDFC NIFTY500 Multicap 50:25:25 Index Fund held 7.62 percent equity stake in the TVS Group company.

The brisk action was also seen in PNGS Reva Diamond Jewellery, which outperformed the falling market, rising 6.66 percent to Rs 411.7 on the NSE despite institutional investors offloading 1.49 percent stake on its listing day today.

The Asio Fund VCC-Sub Fund 4, and Vikasa India EIF I Fund - Share Class P each sold 2.36 lakh shares in Reva Diamonds (0.74 percent stake each) for Rs 8.87 crore. The selling price for these shares was Rs 375 per share.

Meanwhile, Subhash Phootarmal Rathod has acquired 46 lakh shares in Akme Fintrade (India) at Rs 7.24 per share for Rs 3.33 crore, however, Indian Infotech and Software sold 40 lakh shares at Rs 7.25 per share, valued at Rs 2.9 crore. Both are already investors in the company, holding 3.6 percent, and 1.12 percent stake, respectively.

Airline, tourism stocks drop due to US-Iran tensions, flight cuts., SpiceJet, IndiGo, and tourism shares dropped up to 7 percent., Railway stocks also declined on concerns over travel disruptions.

* Airline, tourism stocks drop due to US-Iran tensions, flight cuts.
* SpiceJet, IndiGo, and tourism shares dropped up to 7 percent.
* Railway stocks also declined on concerns over travel disruptions.

Shares of airline, tourism, and railway firms, including SpiceJet, IndiGo, and Rail Vikas Nigam, fell amid ongoing US-Iran tensions, flight cancellations, and airspace restrictions, raising concerns over profits, passenger movement, and crude oil prices.

shorts/business/spicejet-irctc-itdc-shares-extend-losses-as-us-iran-tensions-drag-for-5th-day

* Airline, tourism stocks drop due to US-Iran tensions, flight cuts.
* SpiceJet, IndiGo, and tourism shares dropped up to 7 percent.
* Railway stocks also declined on concerns over travel disruptions.

Shares of airline and tourism-related firms, including SpiceJet and IndiGo, extended losses on Wednesday as tensions between the US and Iran continued for the fifth day, weighing on investor sentiment.

The decline followed extensions of flight cancellations by several domestic carriers to and from West Asia amid airspace restrictions after military action by the US and Israel against Iran.

On the BSE, shares of <a href="https://www.moneycontrol.com/india/stockpricequote/transportlogistics/spicejet/SJ01">SpiceJet</a> fell over 7 percent. The stock has been declining for the past two trading sessions.

Low-cost carrier <a href="https://www.moneycontrol.com/india/stockpricequote/transportlogistics/interglobeaviation/IA04">IndiGo</a> on March 4 said it cancelled more than 500 overseas flights between February 28 and March 3, 2026, due to the ongoing Middle East tensions. Its shares were trading 4.6 percent lower at Rs 4,310.40 apiece.

"If these cancellations persist for seven days, we estimate they will erase about Rs 32 crore of IndiGo’s profit before tax, equal to about 6 percent of profit before tax in the fourth quarter," HSBC analysts led by Parash Jain said.
<h3><a href="https://www.moneycontrol.com/news/business/markets/indigo-says-over-500-overseas-flights-cancelled-in-last-four-days-due-to-middle-east-tensions-stock-falls-5-what-lies-ahead-13850386.html/amp" target="_blank">IndiGo stock falls 4.5%: What lies ahead?</a></h3>
Tourism-related stocks also traded lower. Shares of Ixigo declined, while India Tourism Development Corporation fell 4 percent. Easy Trip Planners was down 3 percent on the NSE.

Railway-linked stocks were also under pressure amid concerns that prolonged disruptions in air travel could affect passenger movement and last-mile connectivity. Shares of Rail Vikas Nigam Ltd dropped over 5 percent to a fresh 52-week low of Rs 283.20 per share.

Shares of Indian Railway Finance Corporation fell 3 percent, also impacted by a muted response to its Offer For Sale (OFS).

Shares of hospitality firms also declined. Lemon Tree Hotels was down more than 3 percent, Indian Hotels Company stock declined more than 2 percent. EIH Ltd, Chalet Hotels and ITC were down up to 1 percent.

Iran carried out fresh strikes on several Gulf countries in retaliation for the joint attack by Israel and the US. The US and Israel also launched further strikes on Iran. The escalation has raised concerns over possible supply disruptions and a rise in crude oil prices.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

A financial journalist with over 10 years of experience, specialising in tracking stock market movements and fundamental developments that impact investors and the broader economy. A keen observer of global financial markets, I regularly engage with leading market voices to write stories. At Moneycontrol, I focus on decoding market trends, policy shifts and economic changes, driven by a constant passion to learn, analyse, and share knowledge with my readers.

SpiceJet, IRCTC, Indian Hotels, other tourism-related shares extend losses as US-Iran tensions drag for 5th day

Shares of airline and tourism-related firms, including SpiceJet and IndiGo, extended losses on Wednesday as tensions between the US and Iran continued for the fifth day, weighing on investor sentiment.

The decline followed extensions of flight cancellations by several domestic carriers to and from West Asia amid airspace restrictions after military action by the US and Israel against Iran.

On the BSE, shares of SpiceJet fell over 7 percent. The stock has been declining for the past two trading sessions.

Low-cost carrier IndiGo on March 4 said it cancelled more than 500 overseas flights between February 28 and March 3, 2026, due to the ongoing Middle East tensions. Its shares were trading 4.6 percent lower at Rs 4,310.40 apiece.

&quot;If these cancellations persist for seven days, we estimate they will erase about Rs 32 crore of IndiGo’s profit before tax, equal to about 6 percent of profit before tax in the fourth quarter,&quot; HSBC analysts led by Parash Jain said.
IndiGo stock falls 4.5%: What lies ahead?
Tourism-related stocks also traded lower. Shares of Ixigo declined, while India Tourism Development Corporation fell 4 percent. Easy Trip Planners was down 3 percent on the NSE.

Railway-linked stocks were also under pressure amid concerns that prolonged disruptions in air travel could affect passenger movement and last-mile connectivity. Shares of Rail Vikas Nigam Ltd dropped over 5 percent to a fresh 52-week low of Rs 283.20 per share.

Shares of Indian Railway Finance Corporation fell 3 percent, also impacted by a muted response to its Offer For Sale (OFS).

Shares of hospitality firms also declined. Lemon Tree Hotels was down more than 3 percent, Indian Hotels Company stock declined more than 2 percent. EIH Ltd, Chalet Hotels and ITC were down up to 1 percent.

Iran carried out fresh strikes on several Gulf countries in retaliation for the joint attack by Israel and the US. The US and Israel also launched further strikes on Iran. The escalation has raised concerns over possible supply disruptions and a rise in crude oil prices.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

BSE, MCX, and Angel One shares fell up to 4 percent., Sensex and Nifty hit multi-month lows amid West Asia tensions., Crude prices and conflict spark concerns for Indian markets.

* BSE, MCX, and Angel One shares fell up to 4 percent.
* Sensex and Nifty hit multi-month lows amid West Asia tensions.
* Crude prices and conflict spark concerns for Indian markets.

Shares of BSE, MCX, and Angel One fell up to 4% as Sensex and Nifty hit multi-month lows amid escalating US-Iran tensions. Rising crude prices and uncertainty over the conflict weighed on investor sentiment, impacting all Nifty Capital Market index constituents.

shorts/business/us-iran-tensions-bse-mcx-other-capital-market-stocks-fall-up-to-4-as-sensex-crashes-2-500-pts-in-two-days

* BSE, MCX, and Angel One shares fell up to 4 percent.
* Sensex and Nifty hit multi-month lows amid West Asia tensions.
* Crude prices and conflict spark concerns for Indian markets.

Shares of capital market-linked firms BSE, Multi Commodity Exchange (MCX) and Angel One fell up to 4 percent on Wednesday as benchmark indices extended losses amid escalating tensions between the US and Iran.

The <a href="https://www.moneycontrol.com/news/business/markets/sensex-crashes-1-700-pts-nifty-below-24-400-raging-middle-east-conflict-among-key-factors-behind-market-decline-13850163.html" target="_blank">Sensex plunged 1,700 points, or 2.24 percent</a>, to hit an 11-month low of 78,443.2. The broader Nifty dropped 2.25 percent to a 10-month low of 24,305.4, tracking a weak global trend as rising hostilities in West Asia pushed crude oil prices higher.

Within the Nifty Capital Market index, <a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/bselimited/B08">BSE</a> was among the top laggards, declining up to 4 percent. It was followed by <a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/multicommodityexchangeindia/MCE">Multi Commodity Exchange of India</a> and Central Depository Services (India), which fell 2.3 percent and 2.93 percent, respectively.

All 15 constituents of the Nifty Capital Market index were trading in the red as the conflict in West Asia entered its fifth day, weighing on investor sentiment.

"With the war escalating and crude oil rising, markets are entering a phase of heightened uncertainty. The duration of the conflict and the extent of the damage remain unclear. For India, which depends on imports for around 85 percent of its oil requirements, the key concern is the impact of higher crude prices on inflation and economic growth," VK Vijayakumar, Chief Investment Strategist at Geojit Investments, said.

Iran carried out fresh strikes on several Gulf countries in retaliation for the joint attack by Israel and the US. The US and Israel also launched further strikes on Iran. The escalation has raised concerns over possible supply disruptions and higher crude oil prices.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

US-Iran tensions: BSE, MCX, other capital market stocks fall up to 4% as Sensex crashes 2,500 pts in two days

Shares of capital market-linked firms BSE, Multi Commodity Exchange (MCX) and Angel One fell up to 4 percent on Wednesday as benchmark indices extended losses amid escalating tensions between the US and Iran.

The Sensex plunged 1,700 points, or 2.24 percent, to hit an 11-month low of 78,443.2. The broader Nifty dropped 2.25 percent to a 10-month low of 24,305.4, tracking a weak global trend as rising hostilities in West Asia pushed crude oil prices higher.

Within the Nifty Capital Market index, BSE was among the top laggards, declining up to 4 percent. It was followed by Multi Commodity Exchange of India and Central Depository Services (India), which fell 2.3 percent and 2.93 percent, respectively.

All 15 constituents of the Nifty Capital Market index were trading in the red as the conflict in West Asia entered its fifth day, weighing on investor sentiment.

&quot;With the war escalating and crude oil rising, markets are entering a phase of heightened uncertainty. The duration of the conflict and the extent of the damage remain unclear. For India, which depends on imports for around 85 percent of its oil requirements, the key concern is the impact of higher crude prices on inflation and economic growth,&quot; VK Vijayakumar, Chief Investment Strategist at Geojit Investments, said.

Iran carried out fresh strikes on several Gulf countries in retaliation for the joint attack by Israel and the US. The US and Israel also launched further strikes on Iran. The escalation has raised concerns over possible supply disruptions and higher crude oil prices.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/natcopharma/NP07">Natco Pharma</a>’s share price rose more than 2 percent in the opening trade on March 4 after the company announced the launch of Pomalidomide Capsules in the US market.

At 09:24am,  Natco Pharma was quoting at Rs 981.00, up Rs 24.60, or 2.57 percent, on the BSE.

Natco Pharma, along with its partner Breckenridge Pharmaceutical, Inc., has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene, in the United States, according to the company’s exchange filing.

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics.

“We are pleased to launch Pomalidomide Capsules in the US. This further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to making specialty medicines accessible to patients worldwide. We look forward to bringing more complex and specialty products to the market in the coming years,” said Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of Natco Pharma.

<a href="https://www.moneycontrol.com/news/business/markets/sensex-today-stock-market-today-live-updates-liveblog-13850027.html">Catch all the market action on our live blog</a>

In February, Eris Lifesciences announced a strategic partnership with Natco Pharma for the commercialisation of Semaglutide in India.

In the previous trading session, the share closed at Rs 956.40, down Rs 31.90, or 3.23 percent. The share touched a 52-week high of Rs 1,059.60 and a 52-week low of Rs 660.05 on 24 July, 2025 and 07 April, 2025, respectively. Currently, the stock is trading 9.74 percent below its 52-week high and 44.9 percent above its 52-week low. The market capitalisation of the company stands at Rs 17,130.07 crore.

Natco Pharma shares rise 2% on Pomalidomide capsules launch in US

Natco Pharma’s share price rose more than 2 percent in the opening trade on March 4 after the company announced the launch of Pomalidomide Capsules in the US market.

At 09:24am,  Natco Pharma was quoting at Rs 981.00, up Rs 24.60, or 2.57 percent, on the BSE.

Natco Pharma, along with its partner Breckenridge Pharmaceutical, Inc., has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene, in the United States, according to the company’s exchange filing.

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics.

“We are pleased to launch Pomalidomide Capsules in the US. This further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to making specialty medicines accessible to patients worldwide. We look forward to bringing more complex and specialty products to the market in the coming years,” said Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of Natco Pharma.

Catch all the market action on our live blog

In February, Eris Lifesciences announced a strategic partnership with Natco Pharma for the commercialisation of Semaglutide in India.

In the previous trading session, the share closed at Rs 956.40, down Rs 31.90, or 3.23 percent. The share touched a 52-week high of Rs 1,059.60 and a 52-week low of Rs 660.05 on 24 July, 2025 and 07 April, 2025, respectively. Currently, the stock is trading 9.74 percent below its 52-week high and 44.9 percent above its 52-week low. The market capitalisation of the company stands at Rs 17,130.07 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/cipla/C">Cipla</a> announced plans to incorporate a joint venture company in India with biologics Contract Development and Manufacturing Organization (CDMO) Kemwell Biopharma.

At 09:24am, Cipla was quoting at Rs 1,332.20, down Rs 19.65, or 1.45 percent, on the BSE.

In a press release, the company said it has entered into a joint venture agreement with Kemwell Biopharma for the incorporation of a JV company in India.

The proposed entity will be a 60:40 joint venture between Cipla and Kemwell, with the partners initially investing up to ₹10 crore in the JV in their respective shareholding ratio.

At the time of incorporation, Cipla will subscribe to 6,000 shares of ₹10 each at par, amounting to ₹60,000.

The joint venture will undertake the business of developing, applying for and obtaining licenses for, and manufacturing, commercialising, importing and exporting biologic products. It will also engage in licensing or outsourcing any or all of such activities.

Kemwell is an Asia-based biologics CDMO offering end-to-end services for global biopharma clients. Its Bengaluru-based cGMP facility, certified by the USFDA, houses 5,000-litre bioreactor capacity, sterile fill–finish capabilities, and advanced development laboratories for protein therapeutics.

The company supports commercial manufacturing as well as R&amp;D and clinical programs for novel biologics and biosimilars.

<a href="https://www.moneycontrol.com/news/business/markets/sensex-today-stock-market-today-live-updates-liveblog-13850027.html">Catch all the market action on our live blog</a>

In another development, its wholly owned subsidiary, Cipla (EU) Limited, UK, has incorporated a new wholly owned subsidiary, ‘Cipla Middle East Company’, in the Kingdom of Saudi Arabia.

In the previous trading session, the share closed at Rs 1,351.85, up Rs 4.20, or 0.31 percent. The share touched a 52-week high of Rs 1,672.20 and a 52-week low of Rs 1,283.00 on 23 October, 2025 and 27 January, 2026, respectively. Currently, the stock is trading 19.16 percent below its 52-week high and 5.37 percent above its 52-week low. The market capitalisation stands of the company stands at Rs 109,199.83 crore.

Cipla to form JV with Kemwell Biopharma; share price down marginally

Cipla announced plans to incorporate a joint venture company in India with biologics Contract Development and Manufacturing Organization (CDMO) Kemwell Biopharma.

At 09:24am, Cipla was quoting at Rs 1,332.20, down Rs 19.65, or 1.45 percent, on the BSE.

In a press release, the company said it has entered into a joint venture agreement with Kemwell Biopharma for the incorporation of a JV company in India.

The proposed entity will be a 60:40 joint venture between Cipla and Kemwell, with the partners initially investing up to ₹10 crore in the JV in their respective shareholding ratio.

At the time of incorporation, Cipla will subscribe to 6,000 shares of ₹10 each at par, amounting to ₹60,000.

The joint venture will undertake the business of developing, applying for and obtaining licenses for, and manufacturing, commercialising, importing and exporting biologic products. It will also engage in licensing or outsourcing any or all of such activities.

Kemwell is an Asia-based biologics CDMO offering end-to-end services for global biopharma clients. Its Bengaluru-based cGMP facility, certified by the USFDA, houses 5,000-litre bioreactor capacity, sterile fill–finish capabilities, and advanced development laboratories for protein therapeutics.

The company supports commercial manufacturing as well as R&amp;amp;D and clinical programs for novel biologics and biosimilars.

Catch all the market action on our live blog

In another development, its wholly owned subsidiary, Cipla (EU) Limited, UK, has incorporated a new wholly owned subsidiary, ‘Cipla Middle East Company’, in the Kingdom of Saudi Arabia.

In the previous trading session, the share closed at Rs 1,351.85, up Rs 4.20, or 0.31 percent. The share touched a 52-week high of Rs 1,672.20 and a 52-week low of Rs 1,283.00 on 23 October, 2025 and 27 January, 2026, respectively. Currently, the stock is trading 19.16 percent below its 52-week high and 5.37 percent above its 52-week low. The market capitalisation stands of the company stands at Rs 109,199.83 crore.

Containers & Packaging Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Containers & Packaging industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q3 FY25-26

Stock News

HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners

SpiceJet, IRCTC, Indian Hotels, other tourism-related shares extend losses as US-Iran tensions drag for 5th day

US-Iran tensions: BSE, MCX, other capital market stocks fall up to 4% as Sensex crashes 2,500 pts in two days

Natco Pharma shares rise 2% on Pomalidomide capsules launch in US

Cipla to form JV with Kemwell Biopharma; share price down marginally

Containers & Packaging Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Containers & Packaging industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q3 FY25-26

Stock News

HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners

SpiceJet, IRCTC, Indian Hotels, other tourism-related shares extend losses as US-Iran tensions drag for 5th day

US-Iran tensions: BSE, MCX, other capital market stocks fall up to 4% as Sensex crashes 2,500 pts in two days

Natco Pharma shares rise 2% on Pomalidomide capsules launch in US

Cipla to form JV with Kemwell Biopharma; share price down marginally

Containers & Packaging Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Containers & Packaging industry stocks.